Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Jun. 2026,
Sanofi paidCHF913 Mil more to buy back shares than it received from issuing new shares.
It receivedCHF2,401 Mil from issuing more debt.
It paidCHF0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spentCHF4,533 Mil paying cash dividends to shareholders.
It spentCHF23 Mil on other financial activities.
In all, SanofispentCHF3,068 Mil on financial activities for the
six
months ended in Jun. 2026.
Sanofi (XSWX:SAN) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Sanofi's issuance of stock for the
six
months ended in Jun. 2026 was CHF17 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Sanofi's repurchase of stock for the
six
months ended in Jun. 2026 was CHF-929 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Sanofi's net issuance of debt for the
six
months ended in Jun. 2026 was CHF2,401 Mil.
Sanofi receivedCHF2,401 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Sanofi's net issuance of preferred for the
six
months ended in Jun. 2026 was CHF0 Mil.
Sanofi paidCHF0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Sanofi's cash flow for dividends for the
six
months ended in Jun. 2026 was CHF-4,533 Mil.
Sanofi spentCHF4,533 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Sanofi's other financing for the
six
months ended in Jun. 2026 was CHF-23 Mil.
Sanofi spentCHF23 Mil on other financial activities.
Sanofi Cash Flow from Financing Related Terms
Sanofi Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Sanofi's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Sanofi's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-6,538 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of CHF-6,538 Mil mean?
Sanofi (XSWX:SAN) has a Cash Flow from Financing of CHF-6,538 Mil as of Jun. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Sanofi and its competitors.
Is Sanofi's Cash Flow from Financing too high?
Sanofi's current Cash Flow from Financing is CHF-6,538 Mil. Overall, Sanofi has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Cash Flow from Financing compare to LLY and JNJ?
Sanofi's Cash Flow from Financing of CHF-6,538 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Sanofi and its competitors. Sanofi's current Cash Flow from Financing is CHF-6,538 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Sanofi (XSWX:SAN) has a current Cash Flow from Financing of CHF-6,538 Mil. The stock's GF Value™ is CHF103.32, compared to a current price of CHF73.20 — trading 29.2% below its estimated fair value. The current Cash Flow from Financing is CHF-6,538 Mil. Sanofi's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Sanofi (XSWX:SAN), the current Cash Flow from Financing is CHF-6,538 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi (XSWX:SAN) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi stock appears to be undervalued.
The current stock price of CHF73.20 is trading 29.2% below its estimated GF Value™ of CHF103.32.
Key valuation signals for XSWX:SAN:
Cash Flow from Financing: CHF-6,538 Mil
GF Value™: CHF103.32 vs. price of CHF73.20 (29.2% below fair value)
No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
91GF Score
Get the complete analysis for XSWX:SAN
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SAN has been successfully added to your 
